Navigation Links
Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets
Date:11/2/2011

CAPE CORAL, Fla., Nov. 2, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk - News) announced that it has reached an agreement in principal with the inventor of a formula that could have life changing results for hundreds of millions of people worldwide afflicted with the disease. It is expected that the formal agreement will be executed in the coming week, at which point details of the product will be released.

Robert deZanger, CEO of Natures Bioceuticals stated, "The implications of this natural medicine formula are mind boggling both in terms of the increased quality of life to the people who need it and the potential revenues to the company. There are over 20 different prescription drugs for this condition currently on the market and many of them have multi-billion dollar annual sales. We are anxious to have the formal closing and transfer of the rights as soon as possible so we can file a patent on the formula. We will then immediately start clinical trials to validate the veracity of the initial study. If the new expanded control group responds in a similar manner to the initial result this should be a product that will have far reaching implications and should generate acquisition interest from the major pharmaceutical and natural product companies. I look forward to further disclosure, in the very near future, pertaining to this exciting formula."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com


'/>"/>
SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Natures Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
5. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
6. Graphenes quantum leap takes electronics a step closer
7. Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank
8. Cephalon to Release Second Quarter 2011 Earnings Results After the Market Close on August 2, 2011
9. Nanoengineers invent new biomaterial that more closely mimics human tissue
10. UCLA researchers now 1 step closer to controlled engineering of nanocatalysts
11. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Maryland (PRWEB) , ... January 18, 2017 , ... ... two new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce ... in Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers are ... Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including Pfizer, ... such as trial performance metrics, patient enrollment diversity, protocol optimization, and global site ...
(Date:1/18/2017)... ... 2017 , ... Thirty-six startup companies in University City and Center City have ... and Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax ... Zone and represent the highest number of awards to the largest number of companies ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
Breaking Biology Technology:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):